Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound aims to spot twin pregnancy complications before they start

NCT ID NCT07667647

Knowledge-focused Sponsor: Carilion Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a new, high-speed ultrasound device on 10 healthy women pregnant with identical twins who share a placenta. The goal is to see if the device can take detailed pictures of the tiny blood vessels in the placenta. This information could help doctors better understand and eventually predict twin-twin transfusion syndrome, a serious condition where blood flow between twins becomes uneven.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Verasonics Vantage 256 ultrasound device
What this could lead to
If successful, this could lead to better ways to detect and understand twin-twin transfusion syndrome (TTTS) early, potentially improving outcomes for at-risk pregnancies.
What could go wrong
This is a very small, early feasibility study with only 10 participants. It is not designed to prove the device improves health outcomes, only that it can take detailed images.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject is 18 to 45 years of age at screening 2. Non-anomalous, monochorionic, diamniotic (MoDi) or monochorionic, monoamniotic (MoMo) twin gestation without suspected genetic disorders 3. Low-risk aneuploidy screening, if performed 4. Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC) 5. Anatomical survey has been performed 6. 18 - 26 weeks gestational age 8\. Subject willing and able to provide/re-provide informed consent Exclusion Criteria: 1. Suspected fetal genetic disorder(s) 2. Suspected fetal infection(s), twin-twin transfusion syndrome (TTTS), twin reversed arterial perfusion sequence (TRAPS), or maternal vascular disease 3. Non-English reading and speaking 4. Unstable housing or transportation 5. Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Monochorial monoamniotic placenta are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

twin to twin transfusion syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Monochorial monoamniotic placenta Monochorionic diamniotic placenta Monochorionic twins Pregnancy Twin pregnancy, monochorionic Twin twin transfusion syndrome Ultrasound Ultrasound doppler

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Carilion Clinic, Community Medical Office Building

    Roanoke, Virginia, 24013, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.